Combination chemotherapy with three marginally effective agents, CCNU, vincristine, and bleomycin, in the treatment of stage III melanoma

Cancer Treat Rep. 1976 Sep;60(9):1273-6.

Abstract

Forty-two patients with stage III melanoma were treated with a combination of CCNU, bleomycin, and vincristine. Seventeen of 35 evaluable patients achieved an objective response (48.5%) including five patients with CRs. The median duration of response was 4 months (range, 1-18 months). The responders had a median survival of 278 days (range, 78-1100 days) and the nonresponders had a median survival of 168 days (range 34-619 days). The toxicity off the combination was within an acceptable range with no toxic deaths.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Bleomycin / adverse effects
  • Bleomycin / therapeutic use*
  • Drug Therapy, Combination
  • Female
  • Humans
  • Liver Neoplasms / drug therapy
  • Lomustine / adverse effects
  • Lomustine / therapeutic use*
  • Lung Neoplasms / drug therapy
  • Lymphatic Metastasis
  • Male
  • Melanoma / drug therapy*
  • Middle Aged
  • Neoplasm Metastasis
  • Nitrosourea Compounds / therapeutic use*
  • Skin Neoplasms / drug therapy*
  • Vincristine / adverse effects
  • Vincristine / therapeutic use*

Substances

  • Nitrosourea Compounds
  • Bleomycin
  • Vincristine
  • Lomustine